

## **Apposite Capital Confirms its Commitment to NIMGenetics**

The British firm becomes the majority shareholder of the Spanish genetics company

**London and Madrid – 20<sup>th</sup> September 2021.** Apposite Capital, the healthcare investor, today announces that it has substantially raised its commitment to the Spanish genetics multinational NIMGenetics by increasing the investment already made in 2017. The operation, which places Apposite in a majority shareholding position, reaffirms NIMGenetics leadership position in the clinical genetic diagnosis industry and streamlines corporate decision-making.

One of the first actions since investment was focused on strengthening the team with the incorporation of **Carlos López Borgoñoz**, an international expert in medical and genetic marketing from the Ferrer Group, and **Jaime Vázquez Brull**, as Director of Corporate Development, who has considerable experience in the US and several European countries, with the aim of accelerating NIMGenetics growth in both Iberia and internationally, especially in the area of Pharma and biopharma and supporting the M&A agenda.

In addition, **Alvaro Pérez**, financial analyst joined the finance team to support the M&A and business operations; NIMGenetics also recruited several genetic analysts specialized in genome analysis to reinforce the medical team.

In the last two years, NIMGenetics has diagnosed more than 42,000 patients, with a diagnostic performance above the average in the industry, thanks to its technology and its proprietary bioinformatics algorithms, the deep knowledge of its team and its extensive genetic databases. All this while maintaining its leading position in the field of highly complex clinical genomics (Whole Exome, Clinical Exome and Whole Genome). Furthermore, NIMGenetics offers studies in the field of prenatal diagnosis, such as the TrisoNIM family of products, and women's health, which are very differentiated from the competition.

Following this new commitment from Apposite Capital, the NIMGenetics team is also working on several agreements with national and international biopharmaceutical companies and research centres for the performance of genomic tests in the field of genetic research, compound screening, oncology and gene therapy.

**Enrique Samper**, co-founder and CEO of NIMGenetics, comments: “We are very happy about the renewed commitment by Apposite Capital to the company and its management team. We have prepared ourselves to assume a next stage of growth (organic and acquisitive) with a more professional and solid structure, which will allow us to successfully integrate teams from other companies. We are dedicated to taking NIMGenetics to the next level of value for all the company's stakeholders”.

- end -

**Media contact:**

Anne-Laure Meynier

Tel: +44(0) 20 3475 1710

Email: [anne-laure.meynier@appositecapital.com](mailto:anne-laure.meynier@appositecapital.com)

**About Apposite Capital**

[www.appositecapital.com](http://www.appositecapital.com)

Apposite Capital is an independent investment firm focused exclusively on healthcare. It backs companies operating in health and social care, medtech & medical products, pharmaceuticals & life sciences and digital health.

Apposite Capital operates at the small end of the private equity market, providing both capital and expertise to those businesses offering 'disruptive' models that aim to improve or reduce the cost of care provision and which have the potential to become market leaders.

Apposite has an in-depth sector knowledge covering key aspects of the healthcare industry internationally, an exceptional network and an entrepreneurial mindset which it applies to drive the growth of its portfolio companies.

Apposite Capital was established in 2006 and is headquartered in London, UK.

**About NIMGenetics**

[www.nimgenetics.com](http://www.nimgenetics.com)

NIMGenetics is a Spanish biotechnology multinational specialized in designing and selling clinical genetic diagnostic products and services. With more than 100 employees, it develops exclusive genomic services and products based on two types of technology: microarrays and next-generation sequencing.

Since 2008 NIMGenetics supports specialist clinicians at all stages of the diagnostic process by providing comprehensive genetic approaches and all the pre- and post-testing assistance they could need. The aim of NIMGenetics is to improve the health of patients with genetic diseases, as well as their quality of life and that of their families.

In addition to Spain, NIMGenetics also operates in Portugal, Mexico and Brazil, with a team of highly qualified geneticists. They also have partners in Europe, Latin America and the United States.

*Apposite Capital LLP takes data privacy very seriously, and all reasonable care is taken to comply with the requirements of applicable data privacy laws including the Data Protection Act 2018 and the EU General Data Protection Regulation ("GDPR"). For further information please see our [Data Protection Privacy Notice](#).*